• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by UroGen Pharma Ltd.

    2/3/26 7:53:21 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $URGN alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001763581
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    UroGen Pharma Ltd.
    SEC File Number
    001-38079
    Address of Issuer
    9 HA'TA'ASIYA ST
    RA'ANANA
    ISRAEL
    4365007
    Phone
    972 9 770 7601
    Name of Person for Whose Account the Securities are To Be Sold
    Schoenberg Mark
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Ordinary
    Oppenheimer & Co. Inc
    85 Broad st.
    New York � NY � 10004
    13333261460.134680889202/02/2026
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Ordinary01/31/2023RSUIssuerCheckbox not checked333401/23/2023N/A
    Ordinary01/31/2024RSUIssuerCheckbox not checked333301/31/2024N/A
    Ordinary01/31/2025RSUIssuerCheckbox not checked666601/31/2025N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Mark Schoenberg
    9 HA'TA'ASIYA ST
    RA'ANANA � L3 � 4365007
    Ordinary11/19/202510000250005.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    02/02/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Mark Schoenberg

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $URGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $URGN

    DatePrice TargetRatingAnalyst
    8/19/2025$36.00Overweight
    Piper Sandler
    6/16/2025$50.00Neutral → Buy
    H.C. Wainwright
    5/22/2025Buy → Neutral
    H.C. Wainwright
    4/16/2025$23.00Sector Outperform
    Scotiabank
    2/19/2025$31.00Buy
    Ladenburg Thalmann
    8/22/2024$40.00Buy
    Guggenheim
    2/8/2023$35.00 → $10.00Buy → Hold
    Jefferies
    4/27/2022$20.00Buy
    Berenberg
    More analyst ratings

    $URGN
    SEC Filings

    View All

    SEC Form 144 filed by UroGen Pharma Ltd.

    144 - UroGen Pharma Ltd. (0001668243) (Subject)

    2/3/26 7:53:21 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by UroGen Pharma Ltd.

    SCHEDULE 13G - UroGen Pharma Ltd. (0001668243) (Subject)

    11/14/25 11:26:59 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by UroGen Pharma Ltd.

    S-8 - UroGen Pharma Ltd. (0001668243) (Filer)

    11/6/25 4:29:03 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

    PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patients living with recurrent low-grade intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC) now have improved access to an important therapy, as the permanent Healthcare Common Procedure Coding System Level II J Code for ZUSDURI™ (mitomycin) for intravesical solution became effective on January 1, 2026. The new code, J9282, assigned by the Centers for Medicare & Medicaid Services, is expected to streamline billing and reimbursement proces

    1/5/26 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 14 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) for intravesical solution, UroGen's only approved products, and the continued development of UroGen's pipeline. Up to 32,500 ordinary shares of UroGen are issuable upon the vesting and settlement of t

    12/5/25 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

    PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the Piper Sandler 37th Annual Healthcare Conference to take place on December 2-4, 2025. Piper Sandler 37th Annual Healthcare Conference Date / Time:December 2, 2025, at 1:00 PM ETFormat:Fireside ChatLocation:New York, NYWebcast Link:here   Webcasts from the conferences will also be available on UroGen's Investor Relations website. A replay will be available on the site for approximately 90 days. About UroGen Pharma Ltd. UroGen is a biote

    11/25/25 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Schoenberg Mark converted options into 13,333 units of Ordinary Shares (SEC Form 4)

    4 - UroGen Pharma Ltd. (0001668243) (Issuer)

    2/3/26 5:18:26 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Degnan Chris

    4 - UroGen Pharma Ltd. (0001668243) (Issuer)

    2/3/26 5:16:53 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Holden Stuart converted options into 2,000 units of ordinary shares (SEC Form 4)

    4 - UroGen Pharma Ltd. (0001668243) (Issuer)

    12/1/25 5:17:44 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on UroGen Pharma with a new price target

    Piper Sandler initiated coverage of UroGen Pharma with a rating of Overweight and set a new price target of $36.00

    8/19/25 8:36:26 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded UroGen Pharma from Neutral to Buy and set a new price target of $50.00

    6/16/25 7:44:13 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma downgraded by H.C. Wainwright

    H.C. Wainwright downgraded UroGen Pharma from Buy to Neutral

    5/22/25 8:22:21 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Financials

    Live finance-specific insights

    View All

    UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

    Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial ZUSDURI received unique J-Code (J9282) in October 2025, effective January 1, 2026ZUSDURI achieved net product revenue of $1.8 million in Q3 2025; October 2025 preliminary demand revenue estimate of $4.5 million reflecting accelerating growth entering Q4 2025JELMYTO® achieved net product revenue of $25.7 million in Q3 2025, representing YoY underlying demand revenue growth of 13% $127.4 million in cash, cash equivalents and marketable securities as of September 30, 2025 Conference cal

    11/6/25 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

    PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2025 financial results on Thursday, November 6th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroGen Pharma Ltd. UroG

    10/30/25 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

    ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)JELMYTO® achieved net product sales of $24.2 million in Q2 2025, compared with $21.8 million in Q2 2024, representing 11% year-over-year growth$161.6 million in cash, cash equivalents and marketable securities as of June 30, 2025 Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and spec

    8/7/25 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $URGN
    Leadership Updates

    Live Leadership Updates

    View All

    UroGen Appoints Chris Degnan as Chief Financial Officer

    Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. "Under Don's financial stewardship, we have strengthened our financial position and achieved significant milestones, which include multiple capital raises and investing in the potential commercial launch of UGN-102 for low-grade intermediate-risk non-musc

    10/9/24 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UroGen Pharma Appoints David Lin as New Chief Commercial Officer

    UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen's commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving the continued growth and commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution. David Lin brings to UroGen a wealth of experience garnered from a distinguished career in the pharmaceutical industry. Prior to joining U

    6/3/24 8:00:00 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NorthStar Appoints Peter Pfreundschuh to Board of Managers

    NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

    4/15/24 9:00:00 AM ET
    $FREQ
    $URGN
    $VYGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $URGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by UroGen Pharma Ltd.

    SC 13D/A - UroGen Pharma Ltd. (0001668243) (Subject)

    11/18/24 6:16:04 AM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

    SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

    11/14/24 7:46:37 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

    SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

    11/14/24 5:46:12 PM ET
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care